COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Single Dose Monurol for Treatment of Acute Cystitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00976963
Recruitment Status : Unknown
Verified November 2017 by Ann Stapleton, University of Washington.
Recruitment status was:  Active, not recruiting
First Posted : September 15, 2009
Last Update Posted : November 17, 2017
Information provided by (Responsible Party):
Ann Stapleton, University of Washington

Brief Summary:

Urinary tract infecton (UTI) is a very common problem in young healthy women, afflicting approximately one-half of women by their late 20's. One of the most common antibiotics used to treat UTIs is Trimethoprim-sulfa (TMP-SMX), usually for total of three days. However, concerns about increased antibiotic resistance have led to increased interest in studying other antibiotics for UTI.

An alternative antibiotic which is also FDA approved for the treatment of UTIs is fosfomycin (Monurol). The effectiveness of fosfomycin in curing UTIs when given as a single dose is not well studied. The purpose of this research study is to determine what the cure rates are with a single dose of fosfomycin versus the more standard 3-day course of TMP-SMX.

Condition or disease Intervention/treatment Phase
Urinary Tract Infection Drug: Fosfomycin Drug: TMP/SMX DS Not Applicable

Detailed Description:

Procedures subjects will undergo once they have read and signed the consent are:

Questions about their medical and sexual history and current symptoms of UTI. They will be asked to provide a urine and peri-urethral sample and then are randomly assigned to one of the two treatment groups.They will be given a sheet to record symptoms at home. They will be asked to return to the clinic in 5-8 and 28-30 days after completing antibiotic therapy.Follow-up questions will be asked and urine and peri-urethral will be self collected at each visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Single Dose Monurol for Treatment of Acute Cystitis
Study Start Date : September 2009
Actual Primary Completion Date : June 2017
Estimated Study Completion Date : May 30, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Fosfomycin
Mix sachet with 1/2 glass cold water and stir. Drink immediatley
Drug: Fosfomycin
3g sachet single dose
Other Name: Monurol

Active Comparator: TMP/SMX
Sulfamethoxazole-Trimethoprim 800-160 MG Oral Tab (TMP/SMX) Take one twice daily for 3 days for urinary tract infection
160/800mg BID x 3 days
Other Name: Septra

Primary Outcome Measures :
  1. To assess the efficacy of a single dose fosfomycin [ Time Frame: 28-30 post therapy ]

Secondary Outcome Measures :
  1. To assess the tolerance of a single does of fosfomycin [ Time Frame: 28-30 days post therapy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Non pregnant women in good health with symptoms of acute cystitis for less than 7 days

Exclusion Criteria:

  • Pregnant, lactating, or not regularly contracepting
  • History of chronic conditions such as diabetes
  • Known anatomic abnormalities of the urinary tract
  • Use of prophylactic antibiotics
  • History of allergy or intolerance to any of the study drugs
  • Recent (> 2 weeks)exposure to oral or parenteral antimicrobial
  • History of UTI in previous 1 month

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00976963

Layout table for location information
United States, Washington
University of Washington
Seattle, Washington, United States, 98195
Sponsors and Collaborators
University of Washington
Layout table for investigator information
Principal Investigator: Ann E. Stapleton, M.D. University of WA

Layout table for additonal information
Responsible Party: Ann Stapleton, Professor, Medicine, Infectious Diseases, University of Washington Identifier: NCT00976963    
Other Study ID Numbers: 34776
First Posted: September 15, 2009    Key Record Dates
Last Update Posted: November 17, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Ann Stapleton, University of Washington:
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Tract Infections
Urologic Diseases
Urinary Bladder Diseases
Anti-Bacterial Agents
Anti-Infective Agents